Zorn Julia, Schwamberger Sabine, Panzer Werner, Adler Heiko, Kolb Hans-Jochem
Helmholtz Zentrum München - National Research Center for Environmental Health, Institute of Molecular Immunology, Clinical Cooperation Group Hematopoietic Cell Transplantation, Marchioninistrasse 25, D-81377 Munich, Germany.
Vet Immunol Immunopathol. 2011 Nov 15;144(1-2):27-35. doi: 10.1016/j.vetimm.2011.06.036. Epub 2011 Jul 2.
Human leukocyte antigen (HLA)-haploidentical stem cell transplantation is an opportunity for nearly all patients lacking an HLA matched stem cell donor. However, graft rejection and graft-versus-host disease (GvHD) as well as infectious complications still result in high treatment-related mortality. Here, we used the dog as a preclinical model for the study of tolerance induction with the aim to optimize and to improve a clinical protocol of haploidentical stem cell transplantation. For this purpose CD6-depleted peripheral blood stem cells (PBSCs) were transfused 6d after transplantation of unmodified bone marrow from dog leukocyte antigen (DLA)-haploidentical littermate donors in order to induce immune tolerance. Besides hematopoietic stem cells CD6-depleted PBSC contain, NK cells and a minority of suppressive CD8-positive cells that may suppress activated T lymphocytes. Recipients were conditioned with, cyclophosphamide and antithymocyte globulin (ATG) preceded by a transfusion of donor buffy coat and either 1, 2 or 3 × 3.3 Gy total body irradiation (TBI). Postgrafting immunosuppression was limited to 30 d of cyclosporine and methotrexate. The additional administration of CD6-depleted PBSCs after unmodified marrow could not prevent GvHD, but it may improve engraftment and chimerism after conditioning with 2 × 3.3 Gy TBI. Reasons for incomplete suppression and possible improvements for clinical applications are discussed.
人类白细胞抗原(HLA)单倍型相合干细胞移植为几乎所有缺乏HLA匹配干细胞供体的患者提供了机会。然而,移植物排斥、移植物抗宿主病(GvHD)以及感染并发症仍然导致较高的治疗相关死亡率。在此,我们将犬作为临床前模型用于研究耐受性诱导,旨在优化和改进单倍型相合干细胞移植的临床方案。为此,在移植来自犬白细胞抗原(DLA)单倍型相合同窝供体的未修饰骨髓6天后,输注去除CD6的外周血干细胞(PBSC)以诱导免疫耐受。除造血干细胞外,去除CD6的PBSC含有NK细胞和少数可能抑制活化T淋巴细胞的抑制性CD8阳性细胞。受体接受环磷酰胺和抗胸腺细胞球蛋白(ATG)预处理,预处理前先输注供体白膜层,并给予1次、2次或3次共3.3 Gy的全身照射(TBI)。移植后免疫抑制限于使用30天的环孢素和甲氨蝶呤。在未修饰骨髓后额外给予去除CD6的PBSC不能预防GvHD,但在用2×3.3 Gy TBI预处理后可能改善植入和嵌合状态。文中讨论了抑制不完全的原因以及临床应用中可能的改进措施。